Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children
NCT ID: NCT04542629
Last Updated: 2020-09-09
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE4
Total Enrollment
140 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-10-01
Study Completion Date
2022-08-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Comparison of the efficacy of Rituximab and ketogenic diet in controlling refractory seizures versus the traditional lines as corticosteroid and trace elements.
2. Improving the management of children with refractory seizures
2. Improving the management of children with refractory seizures
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ketogenic Diet in Pediatric Intractable Epilepsy
NCT06310954
Epilepsy in Children
Epilepsy Intractable
RECRUITING
NA
Intermittent Fasting in Refractory Epilepsy
NCT02311023
Epilepsy
TERMINATED
PHASE2
Efficacy of a Simplified Modified Atkins Diet in Children With Refractory Epilepsy
NCT01899898
Refractory Epilepsy
COMPLETED
PHASE2/PHASE3
Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy
NCT00228969
Refractory Epilepsy
COMPLETED
PHASE2
Microbiome Composition and Biomarker Discovery in Refractory Pediatric Epilepsy
NCT04311242
Epilepsy
WITHDRAWN
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Definition of refractory epilepsy
A task force of the International League Against Epilepsy proposed that drug-resistant epilepsy be defined as failure of adequate trials of two tolerated and appropriately chosen and used antiseizure drug schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom (1)
. This requires application of the intervention at adequate strength/dosage for a sufficient length of time (2)..Terms refractory" intractable", drug-resistant" pharmaco-resistant" have been used interchangeably in several documented literature in different time periods (3). The first antiseizure drug fails in 20 to 40 percent of children with epilepsy; lack of efficacy and side effects contribute to treatment failure (4)
Epidemiology About 10-20 % children with epilepsy develop drug refractory epilepsy (5).In a systematic review of 35 observational studies that included over 13,000 patients with epilepsy and 3900 patients with drug resistant epilepsy( DRE), the pooled prevalence of (DRE) was 30 percent, and the pooled incidence proportion was 15 percent (6).
Risk factors
\- A high number of seizures prior to diagnosis and treatment
\- Genetic or inherited syndromes, for both generalized and localization-related epilepsy, have a better prognosis than symptomatic/cryptogenic epilepsy in both pediatric and adult populations (7).
* Localization-related epilepsy underlies more than half of the cases of DRE in children (8,9).
* Other findings more variably associated with the risk of DRE include a presentation with status epilepticus , a longer duration of epilepsy , a family history of epilepsy , a history of febrile convulsions , abnormal ( ELECTROENCEPHALOGRAM ) EEG findings . An abnormal neurologic examination and/or developmental delays (10,11).
* Some pediatric studies have found that seizure onset in later childhood or adolescence appears to be more likely to be associated with DRE than seizures with onset between the ages of 5 and 10 years (12).
Causes (13,14 ) Epilepsy syndromes
Infancy
• Epilepsy of infancy with migrating focal seizures
* West syndrome
* Dravet syndrome
* Doose syndrome
Childhood
* Lennox-Gastaut syndrome
* Epileptic encephalopathy with continuous spike and wave during sleep
Metabolic
• Pyridoxine dependent epilepsy
• Biotinidase biosynthesis deficiency
• Organic acidemia
• Urea cycle disorders
• Non-ketotic hyperglycinemia
* Aminoacidopathies
* Mitochondrial disorders including Alpers syndrome
* Hashimoto encephalopathy
Structural Abnormality
• Malformations: Neuronal migration defects and neural tube defects
• Neurocutaneous syndromes
,
Infectious/Inflammatory:
,
• Hypoxic ischemic encephalopathy,
• Rasmussen encephalitis
* Stroke
* Tumors
* Mesial temporal sclerosis
Autoimmune epilepsies
: N-methyl-D-aspartate receptor(NMDAR),
Connective tissue disorders
• Systemic lupus erythematosus,
• Wegener's granulomatosis
* , sarcoidsosis,
* celiac disease,
* Crohn's disease,
* Behcet's
* Sjorgren's syndrome,
EVALUATION
A- History and presentation :
The approach depends upon age of onset, accurate description: pre-ictal, ictal, postictal events, precipitating events, seizure types, evolution relation to fever, previous history of febrile seizures (simple/complex), associated non-epileptic events, intake of (ANTI EPILPTIC DRUGS )AEDs with dose, developmental history, sleep history, detailed birth and peri-/antenatal history etc.
B-Clinical examination depends upon anthropometry, syndromic facial dysmorphism, neurocutaneous features and detailed neurological and systemic assessment
C- Pseudo-refractoriness indicates a condition in which seizures persist because the condition has not been adequately treated. The most common causes of pseudo refractory epilepsy include
<!-- -->
1. Inappropriate diagnosis
-Cardiogenic (arrhythmias) and vasovagal events (syncope)
* Parasomnias
* Movement disorders (paroxysmal dyskinesias, cataplexy)
* Psychogenic nonepileptic seizure (PNES) can mimic epileptic seizures. , do not respond to antiseizure drug therapy.
While not without limitations, video-EEG monitoring is the gold standard test for the diagnosis of PNES
2. Bad compliance ; Missed dose
3. Incorrect drug An incorrect diagnosis of seizure classification leading to incorrect drug choice It is not uncommon for diopathic generalized epilepsy syndromes to be unrecognized and inappropriately treated with antiseizure drugs that are more appropriate to localization-related epilepsy .
4. Inadequate dosage
5. Inadequate frequency
6. Enzyme induction, especially if more than one antiepilptic drug AED or other medication is used
7. Inadequate anticonvulsant therapy
D-Investigation for the patients include;
1-EEG Routine EEG is a must for the clinical diagnosis of epilepsy and associated syndrome.
For the majority of patients with epilepsy, routine EEG is sufficient to classify seizure type and to start treatment But for refractory epilepsy ( RE) and a doubtful seizure, video-EEG monitoring is the best diagnostic tool available. 2-Drug level monitor 3-Serum electrolyte, serum glucose 4-MRI brain ; High-resolution MRI helps in isolating the cause of focal epilepsies and to predict long-term outcome and spontaneous remission in patients. In some cases, follow-up MRI reveals an etiology for epilepsy (such as cerebral neoplasm, autoimmune encephalitis) that was not seen on the initial study and requires specific therapies in addition to antiseizure drugs . 5- Metabolic Work up Arterial blood gas (ABG ) Serum ammonia ,lactate Tandem mass screening 6-Genetic Testing as karyotyping , gene sequence ,-Fundus examination The presence of features like dysmorphism, growth retardation, intellectual disability and hypotonia may indicate an underlying genetic syndrome, 7-CSF culture, analysis • Lumbar puncture of infectious process 8-vascuilitis panel Complete blood cell count Erythrocyte sedimentation rate CRP ( C REACTIVE PROTEIN ) VWF Ag (VON WILLEBRAND FACTOR) C 3, 4 (COMPLEMENT 3, 4) Antinuclear AB (ANTIBODY) Antiphospholipid AB Antineutrophil cytoplasmic AB Anti-DNA AB 9-autoimmune encephalitis (Hashimotos ) antithyroid peroxidase AB, anti-TSH receptor AB Anti-NMDA-R AB Anti-MOG AB (if CNS demyelination) abdominal ultrasound and -MRI abdomen;To detect ovarian teratoma as in autoimmune encephalitis
F-Practice recommendations for AED trial:
1. Optimise the dose of each AED by increasing the dose incrementally. If the maximum dose is ineffective introduce a second AED while continuing on the first. If seizure control is achieved, consider tapering the first AED. The advice to "start low and go slow" is appropriate 2. If one or two AEDs are ineffective, rational polytherapy should be explored. 3. Consider using AEDs with different mechanisms of action 4. Avoid using an AED that may worsen or provoke seizures Carbamazepine (CBZ), Oxcarbazepine (OXC), Phenytoin (PHT), Vigabatrin (VGB) and Tiagabine (TGB) may worsen myoclonus and absence seizures
* Gabapentin (GBP) and Lamotrigine (LTG) may worsen myoclonus (Benzodiazepines given intravenously may worsen tonic seizures but may be very useful in treating Lennox-Gastaut and does not contraindicate their use
Background A-Immunotherapy
Evidence that the immune system is involved in the pathogenesis of epilepsy particularly, medically refractory epilepsy, has given rise to the use of adjunctive immunotherapy to slow or change the epileptogenic process.
* The presumed immune therapeutic mechanism (ACTH, corticosteroids, plasmapheresis human immunoglobulin G, rituximab, azathioprine, and cyclophosphamide) is the removal of various neuroimmunological mechanisms involved. However, new models suggest suppression of endogenous brain agent's proconvulsant (neuropeptides) There is limited data of these treatments outside of specific epileptic encephalopathies such as West syndrome, Rasmussen encephalitis, Landau Kleffner and specific antibody mediated encephalitis such as anti NMDA encephalitis a) Corticosteroids: Their immunological mechanisms are inhibition diapedesis and therefore infiltration of lymphocytes to the injured areas, attenuating production of inflammatory humoral mediators (IL-2) and inhibition of leukocyte function (helper T lymphocytes mainly) as well as endothelial cells.
Dose:
Methylprednisolone 30 mg /kg /day for 5 days up to 1 gm /day ,pulsed monthly for 6 months (15).
b) Plasmapheresis: the activity of auto-Abs can be modulated by treatment with IVIGs and by plasma treatment, which consists of the mechanical removal of Abs (16)
c) Human immunoglobulin G:
. IgGIV inhibits activation of innate cells, suppression of the production of proinflammatory cytokines, and soluble factors as tumor necrosis factor and interleukins induced by this factor. In endothelial cells and macrophages, suggesting a mechanism antiepileptic Dose:400 mg.kg /day for 5 days
D--Rituximab:
Rituximab, a chimeric monoclonal antibody that binds to CD20, was the first monoclonal antibody to be approved for clinical use in the therapy of cancer. It is approved for use against indolent B-cell non-Hodgkin's lymphoma (NHL), although its use has expanded significantly beyond that indication to virtually any CD20-positive NHL, and more recently into other areas such as autoimmune disorders
) Rituximab targets CD20, a transmembrane protein present on virtually all B cells from the stage at which they become committed to B-cell development until it is downregulated when they differentiate into antibody-secreting plasma cells (17) Numerous review articles whose primary focus is the action of rituximab in the treatment of RA, systemic lupus erythematosus (SLE) and other autoimmune diseases were published in 2006. Although there is a clear consensus that substantial clinical benefits are associated with rituximab therapy, the exact mechanism(s) by which the B-cell depletion promoted by rituximab ameliorates autoimmune disease activity remains an area of active discussion.(18, 19) The most likely mechanisms have naturally centered on the pathogenic role of B cells in autoimmune disease: these include the potential of B cells to give rise to plasma cells that secrete autoantibodies as well as the ability of autoantigen-specific B cells to present antigens to autoreactive T cells, which leads to T-cell activation, cytokine release and inflammation. In certain cases the results of clinical trials have demonstrated moderate correlations between reduction of autoantibody levels and lessening of disease symptoms, which has emphasized the role of autoantibodies in disease pathology. In other studies such correlations have not been observed, which has led investigators to favor B cell-T cell interactions as the most important in the etiology of tissue injury in autoimmune diseases.
(20 ,21)
B-Dietary Therapy
1. ketogenic diet rationale; The common element of these different approaches is variable reduction in the amount of carbohydrate with appropriate increase in fat.
Diets that produce a state of ketosis are referred to as ''ketogenic" When deprived of glucose through restriction of carbohydrate intake, the human body begins metabolizing fat.In doing so, ketone bodies (acetoacetate, acetone, and hydroxybutyrate) are produced . (22).
KDT is associated with increased mitochondrial biogenesis, oxidative phosphorylation, enhanced gamma-aminobutyric acid (GABA) levels, reduced neuronal excitability and firing, and stabilized synaptic function (23)
Indicated Dietary therapy has been reported as effective in the treatment of seizures associated with glucose transporter 1 deficiency, pyruvate dehydrogenase deficiency, infantile spasms, absence epilepsy, myoclonic atonic epilepsy (Doose syndrome), Dravet syndrome, tuberous sclerosis complex, mitochondrial disorders, Lennox-Gastaut syndrome, Sturge-Weber syndrome, and Rett syndrome (24) Results from the randomized control trial indicated that 38% of children had more than 50% reduction in seizure frequency, and 7% had more than 90% reduction in seizure frequency three months after starting classic ketogenic diet. Retrospective studies reported a higher rate of seizure control (25).
Contraindications Absolute contraindications for the use of diet therapy include carnitine deficiency (primary), carnitine palmitoyltransferase (CPT) I OR II deficiency, carnitine translocase deficiency, β-oxidation defects, pyruvate carboxylase deficiency, and porphyria.
2. trace elements and antioxidants; The equilibrium of trace elements is essential for a healthy nervous system due to their key roles in activation of specific enzyme in many pathways of the central nervous system function metabolism
* Essential trace elements that include zinc, copper, magnesium, and selenium might play a role in the pathogenesis of seizures because of their possible influence on synaptogenesis, their actions on ligand- and voltage-gated ion channels, their effects on membrane lipid peroxidation and turnover of some neurotransmitters, and their roles in immunity (26)
Antioxidative defense mechanisms are important pathways involving trace elements. The accumulation of free radicals may lead to seizures and increases the risk o f their recurrence, because oxidative stress produces peroxidated membrane lipids and damages the cells
. Glutathione peroxidase (GPx) and superoxide dismutase (SOD) are two major enzymes that are involved in antioxidative defense mechanisms.
Selenium (Se), zinc (Zn), and copper (Cu) are important trace elements that participate in the structure of these enzymes patients with intractable epilepsy had significantly decreased levels of serum Se and Zn in comparison to the controlled group(27)
A task force of the International League Against Epilepsy proposed that drug-resistant epilepsy be defined as failure of adequate trials of two tolerated and appropriately chosen and used antiseizure drug schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom (1)
. This requires application of the intervention at adequate strength/dosage for a sufficient length of time (2)..Terms refractory" intractable", drug-resistant" pharmaco-resistant" have been used interchangeably in several documented literature in different time periods (3). The first antiseizure drug fails in 20 to 40 percent of children with epilepsy; lack of efficacy and side effects contribute to treatment failure (4)
Epidemiology About 10-20 % children with epilepsy develop drug refractory epilepsy (5).In a systematic review of 35 observational studies that included over 13,000 patients with epilepsy and 3900 patients with drug resistant epilepsy( DRE), the pooled prevalence of (DRE) was 30 percent, and the pooled incidence proportion was 15 percent (6).
Risk factors
\- A high number of seizures prior to diagnosis and treatment
\- Genetic or inherited syndromes, for both generalized and localization-related epilepsy, have a better prognosis than symptomatic/cryptogenic epilepsy in both pediatric and adult populations (7).
* Localization-related epilepsy underlies more than half of the cases of DRE in children (8,9).
* Other findings more variably associated with the risk of DRE include a presentation with status epilepticus , a longer duration of epilepsy , a family history of epilepsy , a history of febrile convulsions , abnormal ( ELECTROENCEPHALOGRAM ) EEG findings . An abnormal neurologic examination and/or developmental delays (10,11).
* Some pediatric studies have found that seizure onset in later childhood or adolescence appears to be more likely to be associated with DRE than seizures with onset between the ages of 5 and 10 years (12).
Causes (13,14 ) Epilepsy syndromes
Infancy
• Epilepsy of infancy with migrating focal seizures
* West syndrome
* Dravet syndrome
* Doose syndrome
Childhood
* Lennox-Gastaut syndrome
* Epileptic encephalopathy with continuous spike and wave during sleep
Metabolic
• Pyridoxine dependent epilepsy
• Biotinidase biosynthesis deficiency
• Organic acidemia
• Urea cycle disorders
• Non-ketotic hyperglycinemia
* Aminoacidopathies
* Mitochondrial disorders including Alpers syndrome
* Hashimoto encephalopathy
Structural Abnormality
• Malformations: Neuronal migration defects and neural tube defects
• Neurocutaneous syndromes
,
Infectious/Inflammatory:
,
• Hypoxic ischemic encephalopathy,
• Rasmussen encephalitis
* Stroke
* Tumors
* Mesial temporal sclerosis
Autoimmune epilepsies
: N-methyl-D-aspartate receptor(NMDAR),
Connective tissue disorders
• Systemic lupus erythematosus,
• Wegener's granulomatosis
* , sarcoidsosis,
* celiac disease,
* Crohn's disease,
* Behcet's
* Sjorgren's syndrome,
EVALUATION
A- History and presentation :
The approach depends upon age of onset, accurate description: pre-ictal, ictal, postictal events, precipitating events, seizure types, evolution relation to fever, previous history of febrile seizures (simple/complex), associated non-epileptic events, intake of (ANTI EPILPTIC DRUGS )AEDs with dose, developmental history, sleep history, detailed birth and peri-/antenatal history etc.
B-Clinical examination depends upon anthropometry, syndromic facial dysmorphism, neurocutaneous features and detailed neurological and systemic assessment
C- Pseudo-refractoriness indicates a condition in which seizures persist because the condition has not been adequately treated. The most common causes of pseudo refractory epilepsy include
<!-- -->
1. Inappropriate diagnosis
-Cardiogenic (arrhythmias) and vasovagal events (syncope)
* Parasomnias
* Movement disorders (paroxysmal dyskinesias, cataplexy)
* Psychogenic nonepileptic seizure (PNES) can mimic epileptic seizures. , do not respond to antiseizure drug therapy.
While not without limitations, video-EEG monitoring is the gold standard test for the diagnosis of PNES
2. Bad compliance ; Missed dose
3. Incorrect drug An incorrect diagnosis of seizure classification leading to incorrect drug choice It is not uncommon for diopathic generalized epilepsy syndromes to be unrecognized and inappropriately treated with antiseizure drugs that are more appropriate to localization-related epilepsy .
4. Inadequate dosage
5. Inadequate frequency
6. Enzyme induction, especially if more than one antiepilptic drug AED or other medication is used
7. Inadequate anticonvulsant therapy
D-Investigation for the patients include;
1-EEG Routine EEG is a must for the clinical diagnosis of epilepsy and associated syndrome.
For the majority of patients with epilepsy, routine EEG is sufficient to classify seizure type and to start treatment But for refractory epilepsy ( RE) and a doubtful seizure, video-EEG monitoring is the best diagnostic tool available. 2-Drug level monitor 3-Serum electrolyte, serum glucose 4-MRI brain ; High-resolution MRI helps in isolating the cause of focal epilepsies and to predict long-term outcome and spontaneous remission in patients. In some cases, follow-up MRI reveals an etiology for epilepsy (such as cerebral neoplasm, autoimmune encephalitis) that was not seen on the initial study and requires specific therapies in addition to antiseizure drugs . 5- Metabolic Work up Arterial blood gas (ABG ) Serum ammonia ,lactate Tandem mass screening 6-Genetic Testing as karyotyping , gene sequence ,-Fundus examination The presence of features like dysmorphism, growth retardation, intellectual disability and hypotonia may indicate an underlying genetic syndrome, 7-CSF culture, analysis • Lumbar puncture of infectious process 8-vascuilitis panel Complete blood cell count Erythrocyte sedimentation rate CRP ( C REACTIVE PROTEIN ) VWF Ag (VON WILLEBRAND FACTOR) C 3, 4 (COMPLEMENT 3, 4) Antinuclear AB (ANTIBODY) Antiphospholipid AB Antineutrophil cytoplasmic AB Anti-DNA AB 9-autoimmune encephalitis (Hashimotos ) antithyroid peroxidase AB, anti-TSH receptor AB Anti-NMDA-R AB Anti-MOG AB (if CNS demyelination) abdominal ultrasound and -MRI abdomen;To detect ovarian teratoma as in autoimmune encephalitis
F-Practice recommendations for AED trial:
1. Optimise the dose of each AED by increasing the dose incrementally. If the maximum dose is ineffective introduce a second AED while continuing on the first. If seizure control is achieved, consider tapering the first AED. The advice to "start low and go slow" is appropriate 2. If one or two AEDs are ineffective, rational polytherapy should be explored. 3. Consider using AEDs with different mechanisms of action 4. Avoid using an AED that may worsen or provoke seizures Carbamazepine (CBZ), Oxcarbazepine (OXC), Phenytoin (PHT), Vigabatrin (VGB) and Tiagabine (TGB) may worsen myoclonus and absence seizures
* Gabapentin (GBP) and Lamotrigine (LTG) may worsen myoclonus (Benzodiazepines given intravenously may worsen tonic seizures but may be very useful in treating Lennox-Gastaut and does not contraindicate their use
Background A-Immunotherapy
Evidence that the immune system is involved in the pathogenesis of epilepsy particularly, medically refractory epilepsy, has given rise to the use of adjunctive immunotherapy to slow or change the epileptogenic process.
* The presumed immune therapeutic mechanism (ACTH, corticosteroids, plasmapheresis human immunoglobulin G, rituximab, azathioprine, and cyclophosphamide) is the removal of various neuroimmunological mechanisms involved. However, new models suggest suppression of endogenous brain agent's proconvulsant (neuropeptides) There is limited data of these treatments outside of specific epileptic encephalopathies such as West syndrome, Rasmussen encephalitis, Landau Kleffner and specific antibody mediated encephalitis such as anti NMDA encephalitis a) Corticosteroids: Their immunological mechanisms are inhibition diapedesis and therefore infiltration of lymphocytes to the injured areas, attenuating production of inflammatory humoral mediators (IL-2) and inhibition of leukocyte function (helper T lymphocytes mainly) as well as endothelial cells.
Dose:
Methylprednisolone 30 mg /kg /day for 5 days up to 1 gm /day ,pulsed monthly for 6 months (15).
b) Plasmapheresis: the activity of auto-Abs can be modulated by treatment with IVIGs and by plasma treatment, which consists of the mechanical removal of Abs (16)
c) Human immunoglobulin G:
. IgGIV inhibits activation of innate cells, suppression of the production of proinflammatory cytokines, and soluble factors as tumor necrosis factor and interleukins induced by this factor. In endothelial cells and macrophages, suggesting a mechanism antiepileptic Dose:400 mg.kg /day for 5 days
D--Rituximab:
Rituximab, a chimeric monoclonal antibody that binds to CD20, was the first monoclonal antibody to be approved for clinical use in the therapy of cancer. It is approved for use against indolent B-cell non-Hodgkin's lymphoma (NHL), although its use has expanded significantly beyond that indication to virtually any CD20-positive NHL, and more recently into other areas such as autoimmune disorders
) Rituximab targets CD20, a transmembrane protein present on virtually all B cells from the stage at which they become committed to B-cell development until it is downregulated when they differentiate into antibody-secreting plasma cells (17) Numerous review articles whose primary focus is the action of rituximab in the treatment of RA, systemic lupus erythematosus (SLE) and other autoimmune diseases were published in 2006. Although there is a clear consensus that substantial clinical benefits are associated with rituximab therapy, the exact mechanism(s) by which the B-cell depletion promoted by rituximab ameliorates autoimmune disease activity remains an area of active discussion.(18, 19) The most likely mechanisms have naturally centered on the pathogenic role of B cells in autoimmune disease: these include the potential of B cells to give rise to plasma cells that secrete autoantibodies as well as the ability of autoantigen-specific B cells to present antigens to autoreactive T cells, which leads to T-cell activation, cytokine release and inflammation. In certain cases the results of clinical trials have demonstrated moderate correlations between reduction of autoantibody levels and lessening of disease symptoms, which has emphasized the role of autoantibodies in disease pathology. In other studies such correlations have not been observed, which has led investigators to favor B cell-T cell interactions as the most important in the etiology of tissue injury in autoimmune diseases.
(20 ,21)
B-Dietary Therapy
1. ketogenic diet rationale; The common element of these different approaches is variable reduction in the amount of carbohydrate with appropriate increase in fat.
Diets that produce a state of ketosis are referred to as ''ketogenic" When deprived of glucose through restriction of carbohydrate intake, the human body begins metabolizing fat.In doing so, ketone bodies (acetoacetate, acetone, and hydroxybutyrate) are produced . (22).
KDT is associated with increased mitochondrial biogenesis, oxidative phosphorylation, enhanced gamma-aminobutyric acid (GABA) levels, reduced neuronal excitability and firing, and stabilized synaptic function (23)
Indicated Dietary therapy has been reported as effective in the treatment of seizures associated with glucose transporter 1 deficiency, pyruvate dehydrogenase deficiency, infantile spasms, absence epilepsy, myoclonic atonic epilepsy (Doose syndrome), Dravet syndrome, tuberous sclerosis complex, mitochondrial disorders, Lennox-Gastaut syndrome, Sturge-Weber syndrome, and Rett syndrome (24) Results from the randomized control trial indicated that 38% of children had more than 50% reduction in seizure frequency, and 7% had more than 90% reduction in seizure frequency three months after starting classic ketogenic diet. Retrospective studies reported a higher rate of seizure control (25).
Contraindications Absolute contraindications for the use of diet therapy include carnitine deficiency (primary), carnitine palmitoyltransferase (CPT) I OR II deficiency, carnitine translocase deficiency, β-oxidation defects, pyruvate carboxylase deficiency, and porphyria.
2. trace elements and antioxidants; The equilibrium of trace elements is essential for a healthy nervous system due to their key roles in activation of specific enzyme in many pathways of the central nervous system function metabolism
* Essential trace elements that include zinc, copper, magnesium, and selenium might play a role in the pathogenesis of seizures because of their possible influence on synaptogenesis, their actions on ligand- and voltage-gated ion channels, their effects on membrane lipid peroxidation and turnover of some neurotransmitters, and their roles in immunity (26)
Antioxidative defense mechanisms are important pathways involving trace elements. The accumulation of free radicals may lead to seizures and increases the risk o f their recurrence, because oxidative stress produces peroxidated membrane lipids and damages the cells
. Glutathione peroxidase (GPx) and superoxide dismutase (SOD) are two major enzymes that are involved in antioxidative defense mechanisms.
Selenium (Se), zinc (Zn), and copper (Cu) are important trace elements that participate in the structure of these enzymes patients with intractable epilepsy had significantly decreased levels of serum Se and Zn in comparison to the controlled group(27)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Refractory Epilepsy
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RITUXIMAB
rituximab INTRAVENOUS 750MG/m2 every 2 weeks for 2 doses
Group Type
EXPERIMENTAL
RiTUXimab Injection [Rituxan]
Intervention Type
DRUG
375 MG/M2 /WEEK INFUSION
KETOGENIC DIET
The common element of these different approaches is variable reduction in the amount of carbohydrate with appropriate increase in fat.
Diets that produce a state of ketosis are referred to as ''ketogenic"
Group Type
ACTIVE_COMPARATOR
RiTUXimab Injection [Rituxan]
Intervention Type
DRUG
375 MG/M2 /WEEK INFUSION
TRACE ELEMENTS
. Essential trace elements that include zinc, copper, magnesium, and selenium
Group Type
ACTIVE_COMPARATOR
RiTUXimab Injection [Rituxan]
Intervention Type
DRUG
375 MG/M2 /WEEK INFUSION
CORTICOSTEROID
corticosteroid pulse therapy 30 mg /kg /day for 5 days monthly for 6 month
Group Type
ACTIVE_COMPARATOR
RiTUXimab Injection [Rituxan]
Intervention Type
DRUG
375 MG/M2 /WEEK INFUSION
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RiTUXimab Injection [Rituxan]
375 MG/M2 /WEEK INFUSION
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
KETOGENIC DIET
TRACE ELEMENTS
CORTICOSTEROID INJECTION
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 1-Age 1 month up to 17 years 2-Both male and female 3-Epileptic patient on two tolerated and appropriately chosen and used antiepilptic drugs with no response
Exclusion Criteria
* 1-Neonate 2-Epieptic patient on monotherapy 3-Conditions mimic epilepsy 4-Pseudo refractioness 5-Absolute contraindications for the use of diet therapy include carnitine deficiency (primary), carnitine palmitoyltransferase (CPT) I OR II deficiency, carnitine translocase deficiency, β-oxidation defects, pyruvate carboxylase deficiency, and porphyria 6-Contraindication for Rituximab:
1. Hypersensitivity to any component, murine proteins. b. Heart failure c. Active infection
1. Hypersensitivity to any component, murine proteins. b. Heart failure c. Active infection
Minimum Eligible Age
1 Month
Maximum Eligible Age
17 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nancy Alaa
Principle investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emad eldeen Mahmoud Hammad, professor
Role: STUDY_DIRECTOR
aAssiut University Children Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshe SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010 Jun;51(6):1069-77. doi: 10.1111/j.1528-1167.2009.02397.x. Epub 2009 Nov 3.
Reference Type
BACKGROUND
Beleza P. Refractory epilepsy: a clinically oriented review. Eur Neurol. 2009;62(2):65-71. doi: 10.1159/000222775. Epub 2009 Jun 12.
Reference Type
BACKGROUND
Aneja S, Jain P. Refractory epilepsy in children. Indian J Pediatr. 2014 Oct;81(10):1063-72. doi: 10.1007/s12098-014-1533-1. Epub 2014 Aug 9.
Reference Type
BACKGROUND
Dudley RW, Penney SJ, Buckley DJ. First-drug treatment failures in children newly diagnosed with epilepsy. Pediatr Neurol. 2009 Feb;40(2):71-7. doi: 10.1016/j.pediatrneurol.2008.09.021.
Reference Type
BACKGROUND
Kalilani L, Sun X, Pelgrims B, Noack-Rink M, Villanueva V. The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis. Epilepsia. 2018 Dec;59(12):2179-2193. doi: 10.1111/epi.14596. Epub 2018 Nov 13.
Reference Type
BACKGROUND
Berg AT, Kelly MM. Defining intractability: comparisons among published definitions. Epilepsia. 2006 Feb;47(2):431-6. doi: 10.1111/j.1528-1167.2006.00440.x.
Reference Type
BACKGROUND
Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000 Feb 3;342(5):314-9. doi: 10.1056/NEJM200002033420503.
Reference Type
BACKGROUND
Dlugos DJ, Sammel MD, Strom BL, Farrar JT. Response to first drug trial predicts outcome in childhood temporal lobe epilepsy. Neurology. 2001 Dec 26;57(12):2259-64. doi: 10.1212/wnl.57.12.2259.
Reference Type
BACKGROUND
Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B. Early development of intractable epilepsy in children: a prospective study. Neurology. 2001 Jun 12;56(11):1445-52. doi: 10.1212/wnl.56.11.1445.
Reference Type
BACKGROUND
Dlugos DJ. The early identification of candidates for epilepsy surgery. Arch Neurol. 2001 Oct;58(10):1543-6. doi: 10.1001/archneur.58.10.1543.
Reference Type
BACKGROUND
Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012 May 15;78(20):1548-54. doi: 10.1212/WNL.0b013e3182563b19. Epub 2012 May 9.
Reference Type
BACKGROUND
Nikodijevic D, Baneva-Dolnenec N, Petrovska-Cvetkovska D, Caparoska D. Refractory Epilepsy-MRI, EEG and CT scan, a Correlative Clinical Study. Open Access Maced J Med Sci. 2016 Mar 15;4(1):98-101. doi: 10.3889/oamjms.2016.029. Epub 2016 Feb 16.
Reference Type
BACKGROUND
Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994 Jan 15;83(2):435-45.
Reference Type
BACKGROUND
Eisenberg R, Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2006 Jan;2(1):20-7. doi: 10.1038/ncprheum0042.
Reference Type
BACKGROUND
Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol. 2005 Sep;17(5):550-7. doi: 10.1097/01.bor.0000172798.26249.fc.
Reference Type
BACKGROUND
Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol. 2006 May;6(5):394-403. doi: 10.1038/nri1838.
Reference Type
BACKGROUND
Cervenka MC, Kossoff EH. Dietary treatment of intractable epilepsy. Continuum (Minneap Minn). 2013 Jun;19(3 Epilepsy):756-66. doi: 10.1212/01.CON.0000431396.23852.56.
Reference Type
BACKGROUND
Bough KJ, Rho JM. Anticonvulsant mechanisms of the ketogenic diet. Epilepsia. 2007 Jan;48(1):43-58. doi: 10.1111/j.1528-1167.2007.00915.x.
Reference Type
BACKGROUND
Kossoff EH, Zupec-Kania BA, Rho JM. Ketogenic diets: an update for child neurologists. J Child Neurol. 2009 Aug;24(8):979-88. doi: 10.1177/0883073809337162. Epub 2009 Jun 17.
Reference Type
BACKGROUND
Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, Whitney A, Cross JH. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 2008 Jun;7(6):500-6. doi: 10.1016/S1474-4422(08)70092-9. Epub 2008 May 2.
Reference Type
BACKGROUND
Yuen AW, Sander JW. Can magnesium supplementation reduce seizures in people with epilepsy? A hypothesis. Epilepsy Res. 2012 Jun;100(1-2):152-6. doi: 10.1016/j.eplepsyres.2012.02.004. Epub 2012 Mar 8.
Reference Type
BACKGROUND
Hayashi M. Oxidative stress in developmental brain disorders. Neuropathology. 2009 Feb;29(1):1-8. doi: 10.1111/j.1440-1789.2008.00888.x.
Reference Type
BACKGROUND
Kanner AM, Soto A, Gross-Kanner H. Prevalence and clinical characteristics of postictal psychiatric symptoms in partial epilepsy. Neurology. 2004 Mar 9;62(5):708-13. doi: 10.1212/01.wnl.0000113763.11862.26.
Reference Type
BACKGROUND
van Mierlo P, Carrette E, Hallez H, Raedt R, Meurs A, Vandenberghe S, Van Roost D, Boon P, Staelens S, Vonck K. Ictal-onset localization through connectivity analysis of intracranial EEG signals in patients with refractory epilepsy. Epilepsia. 2013 Aug;54(8):1409-18. doi: 10.1111/epi.12206. Epub 2013 May 3.
Reference Type
BACKGROUND
Salmenpera TM, Symms MR, Rugg-Gunn FJ, Boulby PA, Free SL, Barker GJ, Yousry TA, Duncan JS. Evaluation of quantitative magnetic resonance imaging contrasts in MRI-negative refractory focal epilepsy. Epilepsia. 2007 Feb;48(2):229-37. doi: 10.1111/j.1528-1167.2007.00918.x.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CSDIMRE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy
NCT00210652
COMPLETED
PHASE2
Effect of Outpatient Classic Ketogenic Diet in Epileptic Children and Adolescent.
NCT03031028
UNKNOWN
PHASE2
Low Glycemic Index Diet Therapy in Children With Refractory Epilepsy
NCT01645072
UNKNOWN
PHASE3
Comparison Between Efficacy of Daily and Intermittent Low Glycemic Index Therapy Diet
NCT03464487
UNKNOWN
NA
A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy
NCT02201251
COMPLETED
PHASE3
Epigenetics and Gut Microbiota in Children With Epilepsy
NCT04063007
UNKNOWN
NA
Pediatric Epilepsy Study in Subjects 1-24 Months
NCT00044278
COMPLETED
PHASE2
An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy
NCT00210522
COMPLETED
PHASE2
A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.
NCT00425282
COMPLETED
PHASE3
Duration of Anti-convulsant Therapy for Acute Symptomatic Seizure in Acute Encephalitis Syndrome
NCT03181945
UNKNOWN
NA
Study in Pediatric Subjects With Epilepsy
NCT01494584
TERMINATED
PHASE2
Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy
NCT00232596
COMPLETED
PHASE3
A Study of the Pharmacokinetics, Safety and Tolerability of Topiramate in Infants (Age 1-24 Months) With Refractory Partial-onset Seizures
NCT00233012
COMPLETED
PHASE1
A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug
NCT03108729
WITHDRAWN
PHASE3
An Observational Study of the Safety of Topiramate in Adults and Children With Epilepsy
NCT00297323
COMPLETED
Efficacy and Safety of Ketogenic Diet as Adjunctive Treatment in Adults With Refractory Epilepsy
NCT01906398
UNKNOWN
PHASE2
A Study of the Safety of Topiramate Given in Combination With Other Medications in Adults and Children With Seizures
NCT00297349
COMPLETED
Energy Expenditure and Quality of Life in Epilepsy
NCT04546711
WITHDRAWN
A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures
NCT01964560
COMPLETED
PHASE3
Clinical Study of Lamotrigine to Treat Newly Diagnosed Typical Absence Seizure in Children and Adolescents
NCT01431976
COMPLETED
PHASE3
Thalidomide Low Threshold in Epilepsy
NCT01061866
COMPLETED
PHASE1/PHASE2
A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures.
NCT00236691
COMPLETED
PHASE2
Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy
NCT00535392
COMPLETED
PHASE2
Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures
NCT01142193
COMPLETED
PHASE3
Role of the Gut Microbiota in Pediatric Epilepsy
NCT04705298
UNKNOWN
PHASE4